Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 1/20 | 0.35 |
| ▸ | LIPG | Q9Y5X9 | 5/20 | 0.33 |
| ▸ | LIPC | P11150 | 1/20 | 0.33 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.33 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.32 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.32 |
| ▸ | C1S | P09871 | 1/20 | 0.32 |
| ▸ | AGTR2 | P50052 | 6/20 | 0.32 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.31 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.31 |
| ▸ | NAMPT | P43490 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4125903 | 0.84 | NAMPT (0.38) | LIPGLIPCPIP4K2APIP4K2CNAMPT | |
| SCHEMBL4135007 | 0.84 | C1S (0.33) | LIPGLIPCKAT5KAT8MCL1 | |
| SCHEMBL4117665 | 0.82 | LIPG (0.34) | LIPGLIPCPIP4K2APIP4K2CNAMPT | |
| Hydrochloric Acid SCHEMBL3697191 | 0.82 | CYP2A6 (0.37) | LIPGKAT5KAT8MCL1C1S | |
| SCHEMBL4127371 | 0.82 | MAOA (0.35) | LIPGLIPCNAMPT | |
| SCHEMBL4142130 | 0.81 | LIPG (0.34) | LIPGLIPCC1SPIP4K2APIP4K2C | |
| SCHEMBL4125700 | 0.81 | ALDH1A1 (0.38) | NAMPT | |
| SCHEMBL4125605 | 0.81 | LIPG (0.33) | ADAM17LIPGLIPCPIP4K2APIP4K2C | |
| SCHEMBL4125945 | 0.80 | LIPG (0.33) | LIPGLIPCPIP4K2APIP4K2C | |
| SCHEMBL4136589 | 0.80 | LIPG (0.33) | LIPGLIPCPIP4K2APIP4K2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190822-B1 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-12-31 | — | — | EP | disclosed |
| US-20090156642-A1 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156642-A1 | 5-Membered heterocyclic compound | CEL, PGA5, COG5 | ADAM17 1627/4885LIPG 2467/4885LIPC 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.